January industry news: donanemab slows clinical decline of Alzheimer’s disease in Phase II trial
AIdriven research projecting new drug developments, Pharmaceutical technology, Innovating medicine with advanced predictive analytics
In this month’s industry news round-up: donanemab has showed significant slowing of decline in a composite measure of cognition and daily function in patients with early Alzheimer’s, troriluzole has not met the co-primary endpoints of a Phase II/III trial in patients with mild-to-moderate Alzheimer’s disease, NICE has rejected ozanimod as a treatment for relapsing–remitting multiple sclerosis in England and Wales, the European Commission has approved a new intramuscular route of administration for PLEGRIDY® for relapsing–remitting multiple sclerosis, and a new study from CERENOVUS demonstrates cost saving associated with First-Pass Effect in mechanical thrombectomy for treating acute ischemic stroke. Take a...
